This is a randomized, double blind, placebo-controlled study of the effects of intranasal
oxytocin in youths with obesity, ages 12-18 years old. Subjects will be randomized to receive
intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 12 weeks. Study
visits include screening to determine eligibility, 2-part main study visits at baseline, week
8, and week 12, and safety check-in visits at weeks 1, 2, 4, and 6, with a safety follow-up
visit 6 weeks after the last dose of study drug. Study procedures include appetite,
behavioral, metabolic, and endocrine assessments.